Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.

Maczis MA, Maceyka M, Waters MR, Newton J, Singh M, Rigsby MF, Turner TH, Alzubi MA, Harrell JC, Milstien S, Spiegel S.

J Lipid Res. 2018 Dec;59(12):2297-2307. doi: 10.1194/jlr.M085191. Epub 2018 Oct 12.

PMID:
30315000
2.

Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Apr 4;556(7699):135. doi: 10.1038/nature26162.

PMID:
29620732
3.

Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.

Turner TH, Alzubi MA, Sohal SS, Olex AL, Dozmorov MG, Harrell JC.

Breast Cancer Res Treat. 2018 Jul;170(2):221-234. doi: 10.1007/s10549-018-4748-4. Epub 2018 Mar 12.

PMID:
29532339
4.

Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Feb 15;554(7692):378-381. doi: 10.1038/nature25465. Epub 2018 Feb 7. Erratum in: Nature. 2018 Apr 4;556(7699):135.

PMID:
29414946
5.

Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer.

Harrell JC, Shroka TM, Jacobsen BM.

Oncogenesis. 2017 Nov 27;6(11):396. doi: 10.1038/s41389-017-0002-x.

6.

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.

Lundberg A, Lindström LS, Harrell JC, Falato C, Carlson JW, Wright PK, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP.

Clin Cancer Res. 2017 Dec 15;23(24):7512-7520. doi: 10.1158/1078-0432.CCR-17-1535. Epub 2017 Sep 29.

7.

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.

Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T; TEX Trialists Group.

Clin Cancer Res. 2017 Dec 1;23(23):7225-7231. doi: 10.1158/1078-0432.CCR-17-2301. Epub 2017 Sep 29.

8.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MCU.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014. doi: 10.1038/npjbcancer.2015.14.

9.

HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.

Medler TR, Craig JM, Fiorillo AA, Feeney YB, Harrell JC, Clevenger CV.

Mol Cancer Res. 2016 Oct;14(10):994-1008. Epub 2016 Jun 29.

10.

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD.

Cell Cycle. 2016;15(8):1046-59. doi: 10.1080/15384101.2016.1152432.

11.

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL.

Nat Commun. 2015 Dec 21;6:10077. doi: 10.1038/ncomms10077.

12.

Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells.

Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, Perou CM, Wahl GM.

Cell Rep. 2015 Sep 29;12(12):2035-48. doi: 10.1016/j.celrep.2015.08.040. Epub 2015 Sep 10.

13.

CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.

Black JL, Harrell JC, Leisner TM, Fellmeth MJ, George SD, Reinhold D, Baker NM, Jones CD, Der CJ, Perou CM, Parise LV.

Breast Cancer Res Treat. 2015 Jul;152(2):337-46. doi: 10.1007/s10549-015-3458-4. Epub 2015 Jun 24.

14.

Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB.

Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.

15.

A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis.

Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, Knott SR.

Nature. 2015 Apr 16;520(7547):358-62. doi: 10.1038/nature14403. Epub 2015 Apr 8.

16.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group.

Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.

17.

Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.

Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL.

Breast Cancer Res. 2014 Oct 30;16(5):462. doi: 10.1186/s13058-014-0462-2.

18.

Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.

Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H.

Cancer Res. 2014 Dec 15;74(24):7406-17. doi: 10.1158/0008-5472.CAN-14-1188. Epub 2014 Oct 22.

19.

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.

Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D.

Breast Cancer Res Treat. 2014 Apr;144(3):503-17. doi: 10.1007/s10549-014-2887-9. Epub 2014 Feb 25.

PMID:
24567196
20.

Taxonomy of breast cancer based on normal cell phenotype predicts outcome.

Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ, Tamimi RM, Ince TA.

J Clin Invest. 2014 Feb;124(2):859-70. doi: 10.1172/JCI70941. Epub 2014 Jan 27.

21.

Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.

Xiao L, Harrell JC, Perou CM, Dudley AC.

Angiogenesis. 2014 Jul;17(3):511-8. doi: 10.1007/s10456-013-9409-y. Epub 2013 Nov 21.

22.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM.

Genome Biol. 2013 Nov 12;14(11):R125. doi: 10.1186/gb-2013-14-11-r125.

23.

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM.

Breast Cancer Res Treat. 2013 Nov;142(2):237-55. doi: 10.1007/s10549-013-2743-3. Epub 2013 Oct 27.

24.

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.

Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM.

Clin Exp Metastasis. 2014 Jan;31(1):33-45. doi: 10.1007/s10585-013-9607-4. Epub 2013 Aug 22.

25.

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2013 Jan;137(2):431-48. doi: 10.1007/s10549-012-2377-x. Epub 2012 Dec 18.

26.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

27.

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL.

Breast Cancer Res. 2012 Jul 5;14(4):R100. doi: 10.1186/bcr3219.

28.

SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.

Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL.

J Clin Invest. 2012 May;122(5):1895-906. doi: 10.1172/JCI59858. Epub 2012 Apr 2.

29.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.

30.

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2742-7. doi: 10.1073/pnas.1106509108. Epub 2011 Oct 3.

31.

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM.

Breast Cancer Res Treat. 2012 Apr;132(2):523-35. doi: 10.1007/s10549-011-1619-7. Epub 2011 Jun 14.

32.

Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers.

Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA.

Mol Cancer Res. 2011 Jan;9(1):3-13. doi: 10.1158/1541-7786.MCR-10-0372. Epub 2010 Dec 3.

33.

Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Nov 1;70(21):8927-36. doi: 10.1158/0008-5472.CAN-10-1238. Epub 2010 Oct 19.

34.

Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.

Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Apr 1;70(7):2655-64. doi: 10.1158/0008-5472.CAN-09-4373. Epub 2010 Mar 23.

35.

The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.

Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.

J Clin Invest. 2009 Sep;119(9):2678-90. doi: 10.1172/JCI37815. Epub 2009 Aug 24.

36.

Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.

Massart F, Federico G, Harrell JC, Saggese G.

Neuroendocrinology. 2009;90(3):307-14. doi: 10.1159/000231994. Epub 2009 Jul 30.

PMID:
19641297
37.

Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.

Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9. doi: 10.1073/pnas.0706216105. Epub 2008 Apr 7.

38.

Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.

Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB.

Cancer Res. 2007 Nov 1;67(21):10582-91.

39.
40.

Thyroid outcome during long-term gonadotropin-releasing hormone agonist treatments for idiopathic precocious puberty.

Massart F, Harrell JC, Federico G, Saggese G.

J Adolesc Health. 2007 Mar;40(3):252-7. Epub 2007 Jan 5.

PMID:
17321426
41.

Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB.

Cancer Res. 2006 Sep 15;66(18):9308-15.

42.

Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium.

Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB.

Cancer Res. 2006 Aug 15;66(16):8274-9.

43.

Lessons in estrogen biology from knockout and transgenic animals.

Hewitt SC, Harrell JC, Korach KS.

Annu Rev Physiol. 2005;67:285-308. Review.

PMID:
15709960
44.

Human breast milk and xenoestrogen exposure: a possible impact on human health.

Massart F, Harrell JC, Federico G, Saggese G.

J Perinatol. 2005 Apr;25(4):282-8. Review.

PMID:
15605068
45.

Update on animal models developed for analyses of estrogen receptor biological activity.

Korach KS, Emmen JM, Walker VR, Hewitt SC, Yates M, Hall JM, Swope DL, Harrell JC, Couse JF.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):387-91. Review.

PMID:
14623535
46.

Genomic structure and identification of a truncated variant message of the mouse estrogen receptor alpha gene.

Swope Dl, Harrell JC, Mahato D, Korach KS.

Gene. 2002 Jul 10;294(1-2):239-47.

PMID:
12234686
47.

AF-2 knock-in mutation of estrogen receptor alpha: Cre-loxP excision of a PGK-neo cassette from the 3' UTR.

Swope DL, Castranio T, Harrell JC, Mishina Y, Korach KS.

Genesis. 2002 Feb;32(2):99-101. No abstract available.

PMID:
11857789
48.

Reproducibility of beam alignment using different bite-wing radiographic techniques.

Potter BJ, Shrout MK, Harrell JC.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Apr;79(4):532-5.

PMID:
7614218
49.

Prostaglandin E2 regulates gingival mononuclear cell immunoglobulin production.

Harrell JC, Stein SH.

J Periodontol. 1995 Mar;66(3):222-7.

PMID:
7776168

Supplemental Content

Loading ...
Support Center